Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Look Better
The $499 monthly price tag is discounted from the drugs typical out-of-pocket cost, which can be more than $1,000
"What we understand is, there will be more than 50 brands that will be launched in the market and there are more than 40 players who will be launching these drugs," Pharmarack's vice president Sheetal Sapale told AFP
NHS Talking Therapies accepts self-referral in most areas of England
A spokesperson for Novo Nordisk confirmed that Ascendis TransCon (transient conjugation) technology is already used in the two commercial drug products Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide)
By activating GLP-1 receptors, these drugs enhance insulin secretion, suppress glucagon release (a hormone that raises blood sugar), and slow gastric emptying, thereby aiding in better blood sugar control
